Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30beaaa993ebfd38cfa2df185ff97bb6 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2005-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85989723839fdc1edf242d1edccf080c |
publicationDate |
2005-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2005261260-A1 |
titleOfInvention |
Combination of a CDK inhibitor and mitoxantrone |
abstract |
A first aspect of the invention relates to a combination comprising a CDK inhibitor and mitoxantrone. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and mitoxantrone as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a CDK inhibitor and mitoxantrone to a subject. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017021177-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004087560-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7858606-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9872874-B2 |
priorityDate |
2002-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |